Recent news on Nesiritide

Short and Long Term Outcomes with Nesiritide for Acute ...  -  Apr 27, 2007
AEM (subscription)Nesiritide is reported to provide benefit in ED Observation Unit (OU) Heart Failure (HF) therapy, however its outcomes are less well defined.

Scios Announces Results From Exploratory Nesiritide Study ...  -  Apr 5, 2007
Drug Newswire (press release),FUSION II was designed to assess the long-term safety and outcomes at six months of once- or twice-weekly infusions of nesiritide compared to placebo in

Nesiritide Fails to Improve Outcomes for at-Home Heart Failure ...  -  Mar 29, 2007
DG NewsNEW ORLEANS, LA -- March 29, 2007 -- An attempt to expand use of the heart failure drug nesiritide (Natrecor) from in-hospital use to at-home use failed to

Nesiritide Safe on Renal Function at Low Doses in Patients With ...  -  Mar 28, 2007
DG NewsNEW ORLEANS, LA -- March 28, 2007 -- Nesiritide therapy at low doses is safe and is not associated with significant deterioration in renal function compared

No nesiritide kidney protection or toxicity seen in acute HF with ...  -  Mar 30, 2007
TheHeart.Org,New Orleans, LA - Until a large, randomized controlled trial that's still in the works sheds a brighter light on the question, concerns that nesiritide may

New perspectives on vasoactive therapy in heart failure management  -  Apr 2, 2007
TheHeart.Org,The role of nesiritide (Natrecor®, Scios/Johnson & Johnson) became controversial after a pooled analysis of three randomized controlled trials published in

ACC: No Role for Outpatient Nisiritide (Natrecor) in Decompensated ...  -  Mar 27, 2007
MedPage Today,NEW ORLEANS, March 27 -- In the largest trial of stage D heart failure, nesiritide (Natrecor) showed no benefit as outpatient therapy, yet there was no

Anemia drug trial's tardiness at issue  -  Apr 20, 2007
Los Angeles Times,More recently, studies have raised questions about the use of nesiritide, a drug made by Johnson & Johnson's Scios unit to treat acute congestive heart

Climbing the Mountain of Acute Decompensated Heart Failure  -  Mar 27, 2007
Journal of American Medical Association (subscription),4 Nesiritide was shown to relieve dyspnea and to reduce pulmonary congestion over the short term, but also was associated with increased intermediate-term

EVEREST Data On Use Of Tolvaptan Published In JAMA And Featured At ACC  -  Mar 31, 2007
Medical News Today (press release),...digoxin, ACE inhibitors, angiotensin II receptor blockers, aldosterone blockers, â-blockers, nitrates, nesiritide and/or hydralazine.

Scios Announces Results From Exploratory Nesiritide Study ...  -  27 Mar 2007
PipelineReview.com (press release),FUSION II was designed to assess the long-term safety and outcomes at six months of once- or twice-weekly infusions of nesiritide compared to placebo in

Is there a role for serial outpatient drug infusions in advanced ...  -  27 Mar 2007
SpiritIndia,The FUSION II trial (Follow-Up Serial Infusions of Nesiritide in Advanced Heart Failure) tested the benefit of a novel drug infusion regimen of serial

EVEREST Data on Short- and Long-Term Use of Otsuka's ...  -  Mar 25, 2007
PR-Inside.com (Pressemitteilung),...digoxin, ACE inhibitors, angiotensin II receptor blockers, aldosterone blockers, beta-blockers, nitrates, nesiritide and/or hydralazine.(1)

Drug safety data need airing, say US researchers  -  Mar 8, 2007
Pharma Times (subscription),These range from Scios' congestive heart failure treatment Natrecor (nesiritide) to the COX-2 inhibitors Vioxx (rofecoxib, Merck & Co) and Bextra

Targeted Renal Therapy for Patients at Risk for Contrast-Induced ...  -  Mar 5, 2007
Business Wire (press release),TRT included: fenoldopam mesylate (92.5 percent of patients), sodium bicarbonate (4.7 percent), alprostadil (2.8 percent) and nesiritide (0.6 percent).

Research Suggests Natrecor(R) (Nesiritide) Improves Postoperative ...  -  Feb 5, 2007
Earthtimes.org5 -- Natrecor(R) (nesiritide) may be beneficial in the prevention of renal dysfunction after coronary artery bypass grafting requiring cardiopulmonary

"Exploratory" study suggests nesiritide protects kidneys during ...  -  Feb 5, 2007
TheHeart.Org,In the Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery (NAPA) study, nesiritide—compared with placebo—was associated with

Research Suggests Nesiritide Improves Postoperative Renal Function ...  -  Feb 5, 2007
DG NewsThose taking Natrecor® (nesiritide) had improved outcomes, including shorter hospital stays and a statistically significant decrease in mortality rate after

Research Suggests Natrecor(R) (Nesiritide) Improves Postoperative ...  -  Feb 5, 2007
Yahoo! News (press release)5 /PRNewswire/ -- Natrecor® (nesiritide) may be beneficial in the prevention of renal dysfunction after coronary artery bypass grafting requiring

No problems seen with addition of nesiritide to heart failure therapy  -  Jan 31, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Concomitant use of intravenous diuretics and positive inotropes along with nesiritide does not appear to lead to any adverse

Drug May Improve Post-Op Outcomes for Bypass Patients  -  Feb 13, 2007
HealthCentral.com,12 (HealthDay News) -- The drug nesiritide (trade name Natrecor) may help prevent kidney dysfunction and improve survival in patients who've had coronary

Bypass patients may benefit from new treatment  -  Feb 12, 2007
Poughkeepsie Journal,The drug nesiritide (trade name Natrecor) may help prevent kidney dysfunction and improve survival in patients who’ve had coronary artery bypass grafting

(PRN) - Black Hills Corporation Announces 37th Consecutive Annual ...  -  Feb 5, 2007
Bolsamania.com,...(PRN) - Research Suggests Natrecor(R) (Nesiritide) Improves Postoperative Renal Function and Potentially Enhances Survival After Coronary Artery Bypass

St. Elizabeth's starts palliative care program  -  Dec 5, 2006
Belleville News-Democrat,The researchers zeroed in on the treatment of heart failure patients after two studies in early 2005 suggested that the drug nesiritide caused an increased

Nesiritide use by clinicians fell fast after negative reports ...  Oct 20, 2006
St Louis, MO - When reports in two prominent journals raised red flags on giving nesiritide (Natrecor, Scios/Johnson & Johnson) to patients with acute ... -TheHeart.Org, ARCA Discovery Names Richard B. Brewer President and Chief ...  Nov 6, 2006
Mr. Brewer was president and CEO of Scios, Inc., where he led the company through the successful approval and launch of Natrecor® (nesiritide), the first new ... -Yahoo! News (press release) Journal Articles Quickly Affect Doctors' Practice  Oct 17, 2006
...the records of nearly 386,000 heart failure patients admitted to 491 US hospitals before and after two articles about the drug nesiritide were published in the ... -Forbes, Study says medical publications can influence doctors  Oct 18, 2006
...in two different medical journals Circulation and the Journal of the American Medical Association which suggested that the use of the drug nesiritide, which is ... -Earthtimes.org Docs heed risks cited in journals, study  Oct 17, 2006
The two articles reported that nesiritide, a popular medication for decompensated heart failure, increased the risk of kidney failure and death. ... -United Press International How Much Influence Do Medical Publications Have On Your Doctor?  Oct 22, 2006
...hospital admissions of heart failure patients before and after two articles appeared in Circulation and JAMA in early 2005 suggesting nesiritide, a popular ... -HealthNewsDigest.com, PHARMACEUTICAL COMPANIES ARE UNDER FEDERAL SCRUTINY FOR PROMOTING ...  Oct 22, 2006
That troubles some doctors who swear by Natrecor, also known as nesiritide. ``I am absolutely enthusiastic,'' said Dr. John Luber Jr., a Tacoma, Wa. ... -San Jose Mercury News, Doctors cautious about prescribing new drugs, study finds  Oct 17, 2006
Louis University researchers, led by Dr. Paul Hauptman, examined the use of nesiritide, a drug approved in 2001 by the Food and Drug Administration to fight ... -St. Louis Post-Dispatch, Doctors act on negative reports in medical journals  Oct 17, 2006
...of heart failure patients before and after two articles were published in the journals JAMA and Circulation about the risks of nesiritide, a medication for ... -CBC.ca, Scripps Health taps leading cardiologist for research institute  Oct 24, 2006
The drug, nesiritide, was designed for patients with acute congestive heart failure, but was being infused in people on an outpatient basis much like ... -San Diego Union Tribune, Risk vs. reward  Oct 23, 2006
University School of Medicine, examined what happened when safety concerns were raised about a new intravenous medicine for heart failure called nesiritide. ... -Belleville News-Democrat, Nesiritide shows hint of survival benefit in chronic-HF patients ...  Sep 12, 2006
Seattle, WA - Perioperative infusion of nesiritide (Natrecor, Scios/Johnson & Johnson) was associated with reductions in mortality over six months among ... -TheHeart.Org

Nesiritide May Reduce Mortality and Adverse Events in Heart ...  Sep 14, 2006
SEATTLE, WA -- September 14, 2006 -- Patients with heart failure (HF) who receive the drug nesiritide (NES) while undergoing cardiac artery bypass graft (CABG ... -DG News

Nesiritide May Inhibit Furosemide-Associated Aldosterone Spikes ...  Sep 14, 2006
SEATTLE, WA -- September 14, 2006 -- Administering an infusion of the drug nesiritide just before bolus dosing of furosemide may mitigate the risky aldosterone ... -DG News

Investigators Report New Renal, Mortality And Safety Data From ...  Sep 12, 2006
Investigators today presented new renal, mortality and safety data from the NAPA (Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery ... -Medical News Today

Investigators Report New Renal, Mortality and Safety Data from ...  Sep 12, 2006
SEATTLE, WA and FREMONT, CA, USA | Sep 11, 2006 | Investigators today presented new renal, mortality and safety data from the NAPA (Nesiritide Administered Peri ... -PipelineReview.com

Investigators Report New Renal, Mortality and Safety Data From ...  Sep 11, 2006
11 /PRNewswire/ -- Investigators today presented new renal, mortality and safety data from the NAPA (Nesiritide Administered Peri-Anesthesia in Patients ... -PR Newswire

Investigators Report New Renal, Mortality and Safety Data From ...  Sep 11, 2006
Calif., September 11, 2006 /PRNewswire/ -- Investigators today presented new renal, mortality and safety data from the NAPA (Nesiritide Administered Peri ... -PharmaLive.com

Scios Selects Duke Clinical Research Institute (DCRI) to Lead ...  Sep 7, 2006
DCRI) as the independent academic research organization that will lead the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated ... -PR Newswire

UPDATE 1-J&J's says Natrecor meets goals in midstage trial  Sep 11, 2006
Scios said adverse events in patients treated with the drug, known by the chemical name nesiritide, occurred at the same overall rate as those on a placebo ... -Reuters

J&J Names Institute to Lead Trial of Its Natrecor Heart Drug  Sep 7, 2006
...expected to cost more than $100 million, the company is making an important investment in the future of the drug, known generically as nesiritide -- albeit a ... -Wall Street Journal (subscription)

NICE Welcomes Referral Of New Work Programme Topics, UK  Aug 31, 2006
Exanta) for atrial fibrillation; lerdelimumab (CAT-152) for glaucoma; carmustine implants (Gliadel Wafers) for glioma (recurrent); nesiritide (Natrecor) for ... -Medical News Today

Scios Announces Selection of Independent Executive Committee and ...  -  12 Dec 2006
PR Newswire (press release),About NATRECOR(R) (nesiritide) NATRECOR(R) added to standard therapy is the only approved treatment for ADHF that has shown improvement in difficulty

Scios Announces Selection of Independent Executive Committee and ...  -  Nov 13, 2006
PR Newswire (press release),NATRECOR(R) (nesiritide) may cause hypotension and should be administered only in settings where blood pressure can be monitored closely.

Scios Announces Selection of Independent Executive Committee and ...  -  Nov 14, 2006
Drug Newswire (press release),...independent executive committee that will lead the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial.

St. Elizabeth's starts palliative care program  -  Dec 11, 2006
Belleville News-Democrat,The researchers zeroed in on the treatment of heart failure patients after two studies in early 2005 suggested that the drug nesiritide caused an increased

(PRN) - Aeronautics Funding, Export-Import Bank Extension ...  -  Nov 13, 2006
Bolsamania.com,...of Independent Executive Committee and Planned Protocol Design for the ASCEND-HF Landmark International Outcomes Trial of NATRECOR(R) (nesiritide) .

Scientist who discovered nesiritide and eptifibatide dies  Jul 14, 2006
San Francisco, CA - Dr Robert M Scarborough, the medicinal chemist who discovered two major cardiovascular drugs— nesiritide (Natrecor, Scios) and ... -TheHeart.Org

AIIMS typhoid vaccine set for commercial streak  Jul 18, 2006
Funded by the department of biotechnology (DBT), the product has been licensed to USV which already has products such as nesiritide, interferons, erythropoietin ... -Financial Express

Corporate donations to MD-run foundations questioned in NY Times ...  Jun 28, 2006
The high-profile controversy about the drug, nesiritide, and its alleged renal toxicity and 30-day mortality risk in patients with acute decompensated HF, have ... -TheHeart.Org

USV set to bag AIIMS' typhoid vaccine tech  Jun 22, 2006
This technology could give USV, an emerging force in biotherapeutics with products such as HGH, Nesiritide, PDGF, IL-2, interferons and erythropoietin in its ... -Business Standard



Nesiritide appears renoprotective in chronic-HF patients ...  May 12, 2006
Washington, DC - Perioperative infusion of nesiritide (Natrecor, Scios) apparently averted kidney damage in patients with chronic heart failure, especially ... - TheHeart.Org

Investigators Report Findings of a Phase 2 Pilot Study Evaluating ...  May 9, 2006
...sponsored pilot trial that included information about the safety of the heart failure drug nesiritide on postoperative renal function and clinical outcomes in ... - Yahoo! News

(PRN) - Perma-Fix Reports Record Profit for First Quarter, Ended ...  May 9, 2006
...[+]. (PRN) - Investigators Report Findings of a Phase 2 Pilot Study Evaluating Postoperative Renal Effects in Heart Failure Patients Treated with Nesiritide ... ... - Bolsamania.com

Not all guidelines on treating heart failure in adults apply to ...  May 2, 2006
Nesiritide, a recombinant B-type natriuretic peptide, is the first new drug approved by the Food and Drug Administration (FDA) in 14 years for the treatment of ... - AAP News (subscription)





The SURVIVE trial failed to demonstrate benefits of Levosimendan ...  Mar 12, 2006
Inotropic agents currently used for acute heart failure, including Dobutamine, Milrinone, and Nesiritide, have been associated with an increased risk of ... - Xagena.it

The Approval of Pfizer's Revatio (Sildenafil) and Servier's ...  Mar 29, 2006
Scios's Natrecor (nesiritide) saw its sales drop amid controversy about its widespread, off-label use in the United States in outpatients. ... - Genetic Engineering News



UPDATE 2-US Medicare denies some J&J heart drug coverage  Mar 2, 2006
Medicare officials said they had also talked to the company about clinical trials of the drug, known generically as nesiritide. ... - Reuters

Head-to-Head Trials Published in the Third Quarter of 2005 ...  Feb 2, 2006
Scios's Natrecor (nesiritide) saw its sales drop amid controversy about its widespread, off-label use in the United States in outpatients. ... - International News Service,

Head-to-Head Trials Published in the Third Quarter of 2005 ...  Feb 2, 2006
Scios's Natrecor (nesiritide) saw its sales drop amid controversy about its widespread, off-label use in the United States in outpatients. ... - International News Service

Biotechnology Industry Veteran Richard Brewer Joins SRI ...  Jan 9, 2006
Previously, Mr. Brewer was CEO and President of Scios Inc., where he led the company in achieving FDA approval for Natrecor(R) (Nesiritide), the first new drug ... - Genetic Engineering News

Off-Label Use of Blood Clotting Drug, NovoSeven, Linked to Deaths ...  Jan 19, 2006
Natrecor, or nesiritide, was approved by the FDA in 2001 to treat congestive heart failure or acute decompensating heart failure in which patients experience ... - Newsinferno.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional